Anti-PD-1 immune checkpoint blockade-based therapy using pembrolizumab in a patient with high-grade glioblastoma. Biomedical Research and Therapy, [S. l.], v. 10, n. 5, p. 5680–5685, 2023. DOI: 10.15419/bmrat.v10i5.809. Disponível em: https://preservation.bmrat.org/index.php/BMRAT/article/view/809.. Acesso em: 15 nov. 2024.